|
|
Article: FDA approves new Zomig (zolmitriptan) nasal spray formulation.
- Article from:
- Drug Week
- Article date:
- October 31, 2003
CopyrightCOPYRIGHT 2003 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2003 OCT 31 - (NewsRx.com & NewsRx.net) -- AstraZeneca (AZN) announced that the U.S. Food and Drug Administration (FDA) has approved Zomig (zolmitriptan) Nasal Spray (5.0 mg) for the acute treatment of migraine with or without aura in adults.
With migraine relief seen as early as 15 minutes, this nasal spray offers a fast acting treatment option for the 28 million Americans who suffer from migraine. In addition, Zomig Nasal Spray has an excellent Nasokinetic profile. This may provide rapid onset of action and a convenient alternative for patients who experience nausea or vomiting in conjunction with their migraine attacks.
Results of a Zomig Nasal Spray ...